Acetyl-CoA carboxylase inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Acetyl-CoA Carboxylase Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Acetyl-CoA Carboxylase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Acetyl-CoA Carboxylase Inhibitors: Overview
Acetyl-CoA carboxylase (ACC) is a biotin-dependent enzyme that catalyzes the irreversible carboxylation of acetyl-CoA to produce malonyl-CoA through its two catalytic activities, biotin carboxylase (BC) and carboxyltransferase (CT). ACC is a multi-subunit enzyme in most prokaryotes and in the chloroplasts of most plants and algae, whereas it is a large, multi-domain enzyme in the cytoplasm of most eukaryotes. The most important function of ACC is to provide the malonyl-CoA substrate for the biosynthesis of fatty acids.
Function - Acetyl-CoA carboxylase catalyzes the carboxylation of acetyl-CoA to malonyl-CoA. Hydrolysis of ATP provides the energy to drive this essentially irreversible reaction. Acetyl-CoA carboxylase is considered the key regulatory enzyme in the conversion of citrate to long-chain fatty acids because (i) the concentrations of its substrates and products are far from thermodynamic equilibrium; (ii) the maximum velocity of the enzyme, as measured in cell extracts under optimal conditions, is usually the slowest of all enzymes in the pathway; (iii) the concentration of the product of the enzyme, malonyl-CoA, increases when flux through the pathway increases.
Acetyl-CoA Carboxylase Inhibitors - With the accumulation of information on the ACC functions and structures in the last decade, a variety of ACC inhibitors have been identified, some of which have been approved for clinical trials.
Acetyl-CoA Carboxylase Inhibitors Emerging Drugs Chapters
This segment of the Acetyl-CoA Carboxylase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acetyl-CoA Carboxylase Inhibitors Emerging Drugs
Further product details are provided in the report……..
Acetyl-CoA Carboxylase Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Acetyl-CoA Carboxylase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Acetyl-CoA Carboxylase Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acetyl-CoA Carboxylase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acetyl-CoA Carboxylase Inhibitors drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Acetyl-CoA Carboxylase Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Acetyl-CoA Carboxylase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Acetyl-CoA Carboxylase Inhibitors: Overview
Acetyl-CoA carboxylase (ACC) is a biotin-dependent enzyme that catalyzes the irreversible carboxylation of acetyl-CoA to produce malonyl-CoA through its two catalytic activities, biotin carboxylase (BC) and carboxyltransferase (CT). ACC is a multi-subunit enzyme in most prokaryotes and in the chloroplasts of most plants and algae, whereas it is a large, multi-domain enzyme in the cytoplasm of most eukaryotes. The most important function of ACC is to provide the malonyl-CoA substrate for the biosynthesis of fatty acids.
Function - Acetyl-CoA carboxylase catalyzes the carboxylation of acetyl-CoA to malonyl-CoA. Hydrolysis of ATP provides the energy to drive this essentially irreversible reaction. Acetyl-CoA carboxylase is considered the key regulatory enzyme in the conversion of citrate to long-chain fatty acids because (i) the concentrations of its substrates and products are far from thermodynamic equilibrium; (ii) the maximum velocity of the enzyme, as measured in cell extracts under optimal conditions, is usually the slowest of all enzymes in the pathway; (iii) the concentration of the product of the enzyme, malonyl-CoA, increases when flux through the pathway increases.
Acetyl-CoA Carboxylase Inhibitors - With the accumulation of information on the ACC functions and structures in the last decade, a variety of ACC inhibitors have been identified, some of which have been approved for clinical trials.
Acetyl-CoA Carboxylase Inhibitors Emerging Drugs Chapters
This segment of the Acetyl-CoA Carboxylase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acetyl-CoA Carboxylase Inhibitors Emerging Drugs
- Firsocostat: Gilead Sciences
- Clesacostat: Pfizer
Further product details are provided in the report……..
Acetyl-CoA Carboxylase Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Acetyl-CoA Carboxylase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Acetyl-CoA Carboxylase Inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Acetyl-CoA Carboxylase Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acetyl-CoA Carboxylase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acetyl-CoA Carboxylase Inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Acetyl-CoA Carboxylase Inhibitors R&D. The therapies under development are focused on novel approaches for Acetyl-CoA Carboxylase Inhibitors.
- Acetyl-CoA Carboxylase Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Acetyl-CoA Carboxylase Inhibitors drugs?
- How many Acetyl-CoA Carboxylase Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Acetyl-CoA Carboxylase Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acetyl-CoA Carboxylase Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acetyl-CoA Carboxylase Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Gilead Sciences
- Pfizer
- Akanocure Pharmaceuticals
- Novo Nordisk
- Firsocostat
- Clesacostat
- AK 1225
- Research programme: acetyl CoA carboxylase 1/2 allosteric inhibitors
- GS 834356
Introduction
Executive Summary
Acetyl-CoA Carboxylase Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Acetyl-CoA Carboxylase Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Acetyl-CoA Carboxylase Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Acetyl-CoA Carboxylase Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Firsocostat: Gilead Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
AK 1225: Akanocure Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Acetyl-CoA Carboxylase Inhibitors Key Companies
Acetyl-CoA Carboxylase Inhibitors Key Products
Acetyl-CoA Carboxylase Inhibitors- Unmet Needs
Acetyl-CoA Carboxylase Inhibitors- Market Drivers and Barriers
Acetyl-CoA Carboxylase Inhibitors- Future Perspectives and Conclusion
Acetyl-CoA Carboxylase Inhibitors Analyst Views
Acetyl-CoA Carboxylase Inhibitors Key Companies
Appendix
Executive Summary
Acetyl-CoA Carboxylase Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Acetyl-CoA Carboxylase Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Acetyl-CoA Carboxylase Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Acetyl-CoA Carboxylase Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Firsocostat: Gilead Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
AK 1225: Akanocure Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Acetyl-CoA Carboxylase Inhibitors Key Companies
Acetyl-CoA Carboxylase Inhibitors Key Products
Acetyl-CoA Carboxylase Inhibitors- Unmet Needs
Acetyl-CoA Carboxylase Inhibitors- Market Drivers and Barriers
Acetyl-CoA Carboxylase Inhibitors- Future Perspectives and Conclusion
Acetyl-CoA Carboxylase Inhibitors Analyst Views
Acetyl-CoA Carboxylase Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Acetyl-CoA Carboxylase Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Acetyl-CoA Carboxylase Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Acetyl-CoA Carboxylase Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Acetyl-CoA Carboxylase Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
